Veronica Di Carlo

Veronica Di Carlo

Auto-generated profile, based on publicly available information

Veronica Di Carlo

Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , Keppel Street, London, WC1E 7HT

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
FGFabio Girardi
Fabio Girardi
VCVeronica Di Carlo
Veronica Di Carlo
CSCharles Stiller
Charles Stiller
GGGemma Gatta
Gemma Gatta
RWRyan R Woods
Ryan R Woods
CAClaudia Allemani
Claudia Allemani
Introduction: Tumors of the central nervous system are among the leading causes of cancer-related death in children. Population-based cancer survival reflects the overall effectiveness of a health care system in managing cancer. Inequity in access to care world-wide may result in survival disparities.Methods: We considered children (0–14 years) diagnosed with a brain tumor during 2000–2014, regardless of tumor behavior. Data underwent a rigorous, three-phase quality control as part of CONCORD-3. We implemented a revised version of the International Classification of Childhood Cancer (third edition) to control for under-registration of non-malignant astrocytic tumors. We estimated net survival using the unbiased nonparametric Pohar Perme estimator.Results: The study included 67,776 children. We estimated survival for 12 histology groups, each based on relevant ICD-O-3 codes. Age-standardized 5-year net survival for low-grade astrocytoma ranged between 84% and 100% world-wide during 2000–2014. In most countries, 5-year survival was 90% or more during 2000–2004, 2005–2009, and 2010–2014. Global variation in survival for medulloblastoma was much wider, with age-standardized 5-year net survival between 47% and 86% for children diagnosed during 2010–2014.Conclusions: To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors in children, by histology. We devised an enhanced version of ICCC-3 to account for differences in cancer registration practices world-wide. Our findings may have public health implications, because low-grade glioma is 1 of the 6 index childhood cancers included by WHO in the Global Initiative for Childhood Cancer.

28 July 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
VCVeronica Di Carlo
Veronica Di Carlo
CSCharles A. Stiller
Charles A. Stiller
NENora Eisemann
Nora Eisemann
ABAndrea Bordoni
Andrea Bordoni
MMMelissa Matz
Melissa Matz
TGthe CONCORD Working Group
the CONCORD Working Group
Background: CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000–2014. Clinical evidence suggests marked international differences in the proportion of lethal acral and nodular subtypes of cutaneous melanoma.Objectives: We aimed to assess whether the differences in morphology may explain global variation in survival.Methods: Patients with melanoma were grouped into the following seven morphological categories: malignant melanoma, not otherwise specified (International Classification of Diseases for Oncology, third revision morphology code 8720), superficial spreading melanoma (8743), lentigo maligna melanoma (8742), nodular melanoma (8721), acral lentiginous melanoma (8744), desmoplastic melanoma (8745) and other morphologies (8722–8723, 8726–8727, 8730, 8740–8741, 8746, 8761, 8770–8774, 8780). We estimated net survival using the nonparametric Pohar Perme estimator, correcting for background mortality by single year of age, sex and calendar year in each country or region. All-ages survival estimates were standardized using the International Cancer Survival Standard weights. We fitted a flexible parametric model to estimate the effect of morphology on the hazard of death.Results: Worldwide, the proportion of nodular melanoma ranged between 7% and 13%. Acral lentiginous melanoma accounted for less than 2% of all registrations but was more common in Asia (6%) and Central and South America (7%). Overall, 36% of tumours were classified as superficial spreading melanoma. During 2010–2014, age-standardized 5-year net survival for superficial spreading melanoma was 95% or higher in Oceania, North America and most European countries, but was only 71% in Taiwan. Survival for acral lentiginous melanoma ranged between 66% and 95%. Nodular melanoma had the poorest prognosis in all countries. The multivariable analysis of data from registries with complete information on stage and morphology found that sex, age and stage at diagnosis only partially explain the higher risk of death for nodular and acral lentiginous subtypes.Conclusions: This study provides the broadest picture of distribution and population-based survival trends for the main morphological subtypes of cutaneous melanoma in 59 countries. The poorer prognosis for nodular and acral lentiginous melanomas, more frequent in Asia and Latin America, suggests the need for health policies aimed at specific populations to improve awareness, early diagnosis and access to treatment.What is already known about this topic? The histopathological features of cutaneous melanoma vary markedly worldwide. The proportion of melanomas with the more aggressive acral lentiginous or nodular histological subtypes is higher in populations with predominantly dark skin than in populations with predominantly fair skin.What does this study add? We aimed to assess the extent to which these differences in morphology may explain international variation in survival when all histological subtypes are combined. This study provides, for the first time, international comparisons of population-based survival at 5 years for the main histological subtypes of melanoma for over 1.5 million adults diagnosed during 2000–2014. This study highlights the less favourable distribution of histological subtypes in Asia and Central and South America, and the poorer prognosis for nodular and acral lentiginous melanomas. We found that later stage at diagnosis does not fully explain the higher excess risk of death for nodular and acral lentiginous melanoma compared with superficial spreading melanoma.

19 March 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
FGFabio Girardi
Fabio Girardi
BRBrian Rous
Brian Rous
CSCharles A Stiller
Charles A Stiller
GGGemma Gatta
Gemma Gatta
NFNaomi Fersht
Naomi Fersht
CAClaudia Allemani
Claudia Allemani
Background: Global variations in survival for brain tumors are very wide when all histological types are considered together. Appraisal of international differences should be informed by the distribution of histology, but little is known beyond Europe and North America. Methods: The source for the analysis was the CONCORD database, a program of global surveillance of cancer survival trends, which includes the tumor records of individual patients from more than 300 population-based cancer registries. We considered all patients aged 0-99 years who were diagnosed with a primary brain tumor during 2000-2014, whether malignant or nonmalignant. We presented the histology distribution of these tumors, for patients diagnosed during 2000-2004, 2005-2009, and 2010-2014. Results: Records were submitted from 60 countries on 5 continents, 67 331 for children and 671 085 for adults. After exclusion of irrelevant morphology codes, the final study population comprised 60 783 children and 602 112 adults. Only 59 of 60 countries covered in CONCORD-3 were included because none of the Mexican records were eligible. We defined 12 histology groups for children, and 11 for adults. In children (0-14 years), the proportion of low-grade astrocytomas ranged between 6% and 50%. Medulloblastoma was the most common subtype in countries where low-grade astrocytoma was less commonly reported. In adults (15-99 years), the proportion of glioblastomas varied between 9% and 69%. International comparisons were made difficult by wide differences in the proportion of tumors with unspecified histology, which accounted for up to 52% of diagnoses in children and up to 65% in adults. Conclusions: To our knowledge, this is the first account of the global histology distribution of brain tumors, in children and adults. Our findings provide insights into the practices and the quality of cancer registration worldwide.

13 August 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
MCMichel P. Coleman
Michel P. Coleman
MMMelissa Matz
Melissa Matz
PMPamela Minicozzi
Pamela Minicozzi
VCVeronica Di Carlo
Veronica Di Carlo
DHDyfed Huws
Dyfed Huws
CAClaudia Allemani
Claudia Allemani
Trends in cancer survival are a key indicator of progress in the effectiveness of the health system in managing cancer. We aimed to provide long-term trends in a one-number index of survival for all cancers combined, to support national cancer policy. We examined long-term trends in a one-number index of net survival (Cancer Survival Index) for all cancers combined in adults in England and Wales. Net survival includes all cancer patients, regardless of whether cancer was the cause of their death. We estimated net survival up to 10 years after diagnosis for 10,769,854 adults diagnosed with a first, primary, invasive cancer during 1971–2018 and followed up to 2019, using anonymised individual records from the National Disease Registration Service for England and the Welsh Cancer Intelligence and Surveillance Unit. We examined trends in the Cancer Survival Index (CSI) at one, five, seven and 10 years after diagnosis, using the entire data set. We present results for selected periods: 1971–72, 1980–81, 1990–91, 2000–01, 2005–06, 2010–11 and 2018. During the 48 years 1971–2018, the CSI for England and Wales rose substantially, at all intervals up to 10 years after diagnosis. For patients diagnosed in 1971–72, the CSI was 46.5% at 1 year after diagnosis. For patients diagnosed in 2018, the index is 49.8% at 10 years after diagnosis. The CSI has remained about 10% higher for women than men since the early 1970s. The speed of improvement has slowed down: between 2000–01 and 2005–06, the 10-year CSI rose by 4.0%. Ten years later, the increase between 2010–11 and 2015–16 was only 1.4%. The slow-down since 2010 of long-term trends in the CSI for all cancers combined in England and Wales is likely to be at least partly explained by longer waits for diagnosis and treatment. A long-term national cancer plan to bring cancer survival trends back towards the best in the world is essential. Cancer Research UK.

13 January 2025 in European Journal of Cancer
Verified
Journal Article
Open access
VCVeronica Di Carlo
Veronica Di Carlo
AEA. Eberle
A. Eberle
CSC. Stiller
C. Stiller
DBD. Bennett
D. Bennett
AKA. Katalinic
A. Katalinic
CAC. Allemani
C. Allemani
CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000-2014. Studies showed a survival advantage in women, but the reasons are not completely understood. We aim to estimate trends in age-standardised 5-year net survival by sex and to examine the role of age, anatomic location and stage on the survival advantage for women worldwide. Patients were grouped into five anatomic locations (head and neck, trunk, limbs, genital organs and not otherwise specified locations), into five age groups (15-29, 30-44, 45-59, 60-74 and 75-99 years) and into binary stage (non-metastatic vs. metastatic). We estimated net survival with the non-parametric Pohar Perme estimator, correcting for background mortality by single-year of age, sex, race/ethnicity where possible and calendar year in each country. All-ages estimates were standardised with the International Cancer Survival Standard weights. Men were generally older and with higher proportion of metastatic melanomas than women. Overall, the trunk was the most common location in men (range 31 %-58 %) and the lower limbs and hips in women (26 %-40 %). Age-standardised 5-year net survival was lower in men (43 %-92 %) than in women (54 %-95 %) in all countries during 2010-2014 and it was lower at older ages for both sexes. A survival advantage for women was observed for all anatomic sites and for localised disease. Women had a more favourable distribution of main prognostic factors, and showed highest survival for any prognostic factor. Public health efforts should focus on raising awareness of early signs of melanoma, especially among elderly in South-East Europe and to increase awareness in East-Asia, where survival was poorest.

14 September 2020 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
VCVeronica Di Carlo
Veronica Di Carlo
JEJacques Estève
Jacques Estève
CJChristopher Johnson
Christopher Johnson
FGFabio Girardi
Fabio Girardi
HWHannah K Weir
Hannah K Weir
CAClaudia Allemani
Claudia Allemani
Background: Survival from metastatic cutaneous melanoma is substantially lower than for localized disease. Treatments for metastatic melanoma have been limited, but remarkable clinical improvements have been reported in clinical trials in the last decade. We described the characteristics of US patients diagnosed with cutaneous melanoma during 2001-2013 and assessed trends in short-term survival for distant-stage disease.Methods: Trends in 1-year net survival were estimated using the Pohar Perme estimator, controlling for background mortality with life tables of all-cause mortality rates by county of residence, single year of age, sex, and race for each year 2001-2013. We fitted a flexible parametric survival model on the log-hazard scale to estimate the effect of race on the hazard of death because of melanoma and estimated 1-year net survival by race.Results: Only 4.4% of the 425 915 melanomas were diagnosed at a distant stage, cases diagnosed at a distant stage are more commonly men, older patients, and African Americans. Age-standardized, 1-year net survival for distant-stage disease was stable at approximately 43% during 2001-2010. From 2010 onward, survival improved rapidly, reaching 58.9% (95% confidence interval = 56.6% to 61.2%) for patients diagnosed in 2013. Younger patients experienced the largest improvement. Survival for distant-stage disease increased in both Blacks and Whites but was consistently lower in Blacks.Conclusions: One-year survival for distant-stage melanoma improved during 2001-2013, particularly in younger patients and those diagnosed since 2010. This improvement may be a consequence of the introduction of immune-checkpoint-inhibitors and other targeted treatments for metastatic and unresectable disease. Persistent survival inequalities exist between Blacks and Whites, suggesting differential access to treatment.